Telix Reports $204M Revenue, Up 63% YOY
Telix today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated…
Read moreNews & Views
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Austria
News,
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by BASG for the detection and…
Read more
Gozellix Receives Permanent HCPCS Code
Telix today announces that its next-generation PSMA PET imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System…
Read more
Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses
News,
Telix today announces that its Telix Manufacturing Solutions (TMS) facility in Brussels South (Seneffe), Belgium, has produced its first Good Manufacturing Practice (GMP)-grade commercial radiopharmaceutical doses and delivered them to…
Read more
Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Italy
News,
Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Italy by the AIFA for…
Read more
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Belgium
News,
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by AFMPS for the detection and…
Read more
Telix Precision Medicine Announces AlFluor™ Radiochemistry Platform
News,
Telix today announces it has launched a novel PET radiochemistry solution based on 18F-aluminium fluoride (AlF), named…
Read more
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
News,
Telix today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual…
Read more
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece
News,
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Greek EOF for the…
Read more
Telix Launches New Prostate Cancer Imaging Agent, Gozellix®, in U.S.
News,
Telix today announces that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is now commercially available nationally in the United…
Read more